All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is a pharmaceutical reporter for the Clinical Trials Arena. Abigail holds a BA (Hons) in Journalism from the University of Central Lancashire. Abigail has an expertise in trial design, cell and gene therapies and neurodegenerative diseases. Contact Abigail

Are DCTs truly more sustainable?

During the pandemic, sponsors and biotechs started running decentralised clinical trials (DCTs) to keep research going when patients had less…
Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setback

US-based biotech Cerevance is continuing an ongoing pivotal study of its Parkinson’s disease candidate despite it showing no benefit compared…
Vaxcyte stock sinks despite Phase II IPD vaccine trial success

Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting all…
WHO releases Lancet papers that delve further into clinical trial guidance

The World Health Organization (WHO) has released a series of papers in The Lancet detailing the work that needs to…
J&J’s NSCLC combo projected to extend survival by one year over Tagrisso

Johnson & Johnson’s (J&J’s) Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by one…

Cassava ends simufilam Alzheimer’s programme after second Phase III failure

Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show…
Surrozen drops hepatitis drug after Phase I flop

Surrozen is dropping its sole clinical asset after the drug failed at Phase I, as the company considers a move…
Podcast: How will biotech and biopharma manage with more funding cuts?

The biotech and biopharma industry has struggled in recent years with a lack of investment. While GlobalData has tracked an…
Rising Sirturo resistance highlights urgent need for new TB therapies

There have been widespread reports that more effort and funding is needed to combat the TB crisis. As more cases…
MacroGenics axes ADC drug following Phase II failure in prostate cancer

MacroGenics is axing the development of one of its antibody-drug conjugates (ADC) after it flopped in a Phase II study…